Boston, MA – October 17, 2013 – Celmatix, a biotechnology company focused on helping physicians guide patients to treatments that maximize their personal reproductive potential, announced today six research presentations at the annual meeting of the American Society for Reproductive Medicine (ASRM), being held October 1217 in Boston. Among the data presented was a new study suggesting that up to 25 percent of patients may be discontinuing assisted reproductive therapies such as in vitro fertilization (IVF) early, while they still have a good chance of having a baby. The clinical study, which was performed on a dataset of over 6,000 patients from study coauthors Reproductive Medicine Associates of New York, showed that 68 percent of women conceived within two cycles. For those who did not conceive in that time frame and chose to discontinue treatment, the data suggested that more than half (60 percent) would have become pregnant if they had proceeded with an additional two treatment cycles. Other Celmatix findings being presented at ASRM include data on genetic markers related to currently unexplained female infertility and IVF success; factors correlated with higher risk of ectopic pregnancy; and an analytical model that predicts the estimated number of cycles needed by a particular couple to achieve live birth using various fertility treatments.
"We are excited to have this opportunity to present our research findings at ASRM, especially our finding that most patients who are initially unsuccessful with fertility treatments still have a significant chance of having a baby," said Piraye Yurttas Beim, PhD, Founder and Chief Executive Officer of Celmatix. "There are so many unanswered questions about why some women struggle with fertility. These questions create difficult decisions for women and their healthcare providers. Our goal is to offer tools and resources that make this process as informed and evidencebased as possible."
The oral abstracts presented by Celmatix were:
- Patients Discontinue Assisted Reproductive Technology (ART) Too Early: The Results of a Large Multiyear Cohort Study
- A Novel Role for Genomic Copy Number Variants in Female Infertility
- Accurate Prediction of the Number of Cycles to Achieve Live Birth
The three poster presentations were:
- Improved Determination of Ectopic Pregnancy Risks in Patients Undergoing In Vitro Fertilization Using TimeToEvent Models
- Whole Genome Sequencing for Female Infertility Biomarker Discovery
- Targeted Resequencing Sheds Light on the Etiology of Unexplained Female Infertility
About Celmatix, Inc.
Founded in 2009, Celmatix is a New York City based biotechnology company focused on helping women overcome infertility by identifying underlying genetic causes for the condition and developing tools and technologies to help optimize treatment outcomes. Celmatix has identified the regions of the human genome that are most likely to influence a woman's fertility potential and are now mining novel genetic biomarkers for different infertility disorders in these regions. Celmatix has also developed the first data analytic models that can predict the cumulative probability of success across the entire fertility treatment journey for a given couple. For more information, visit http://www.celmatix.com.